Close

Syndax Pharmaceuticals (SNDX) and Incyte (INCY) Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/20/2024

1. NFLX
2. TSM
3. ISRG
4. TSLA
5. SPY
6. INFY
7. SNV
8. SMCI
9. SLB
10. PPG


Go back to Syndax Pharmaceuticals (SNDX) and Incyte (INCY) Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology
Incyte Genomics, Inc. (NASDAQ: INCY) Delayed: 52.35 -0.47 (0.89%)
Previous Close $52.82    52 Week High $118.49 
Open $52.97    52 Week Low $55.00 
Day High $53.00    P/E N/A 
Day Low $52.00    EPS $-0.56 
Volume 2,181,297       

(NASDAQ: SNDX) Delayed: 20.80 +0.31 (1.51%)
Previous Close $20.49    52 Week High $18.03 
Open $20.41    52 Week Low $8.97 
Day High $21.12    P/E N/A 
Day Low $20.36    EPS $0.00 
Volume 942,562